Welcome to our dedicated page for Hemostemix news (Ticker: HMTXF), a resource for investors and traders seeking the latest updates and insights on Hemostemix stock.
Hemostemix Inc. (HMTXF) is a clinical-stage biotechnology leader advancing autologous stem cell therapies for cardiovascular and degenerative conditions. This page aggregates all official announcements, trial updates, and strategic developments directly from the company and verified sources.
Investors and researchers will find timely updates on clinical progress, regulatory milestones, manufacturing innovations, and partnership announcements. Key focus areas include advancements in the company’s patented Automated Cell Therapy System (ACTS), trial results for peripheral arterial disease treatments, and global expansion initiatives across North American and European markets.
Content is curated to provide actionable insights with no-option patient treatment developments, peer-reviewed study references, and financial disclosures. Bookmark this page or check regularly to stay informed about Hemostemix’s progress in delivering evidence-based regenerative therapies through its proprietary blood-derived cell platform.
Hemostemix (OTCQB: HMTXF) has announced a significant expansion of its marketing team to drive sales of its VesCell™ (ACP-01) therapy in Florida. The company has appointed three key executives: Croom Lawrence as Chief Commercial Officer, bringing 25+ years of biotech launch experience, Sana Farooqui as Fractional Chief Marketing Officer, and Bob Branch as Fractional VP of Digital Marketing & Media.
Under Florida's Right-to-Try statute, VesCell™ can now be offered to qualifying patients for treating conditions including PAD, CLTI, angina, and various cardiomyopathies. The therapy has shown promising results in multiple clinical trials, demonstrating improved circulation, reduced amputation needs, and enhanced cardiac function.
Hemostemix (OTCQB: HMTXF) has announced a new partnership with Empire Market Ventures (EMV), a New York City-based consulting firm specializing in investor market awareness and strategic communications. EMV will provide market awareness services to enhance Hemostemix's visibility in the capital markets.
The partnership aims to leverage EMV's expertise in digital media and market intelligence to develop comprehensive investor engagement strategies. EMV will operate independently and at arm's length from Hemostemix to ensure unbiased guidance and regulatory compliance.
Hemostemix (OTCQB: HMTXF) has increased its previously closed non-brokered private placement from $2,969,600 to $3,000,000 through the issuance of 3,000,000 additional units at $0.10 per unit. Each unit comprises one common share and one warrant exercisable at $0.15 for 24 months.
The company paid $100,032 in finder's fees and issued 1,000,320 finder's options. The proceeds will be used to repay CD#1 at a 50% discount ($1,250,000) and for general working capital. The offering constitutes a related party transaction, with directors Peter Lacey and Loran Swanberg participating. Following the offering, Mr. Lacey's ownership increased to 13.40% of outstanding shares (non-diluted) and 15.6% on a partially diluted basis.
Hemostemix (OTCQB: HMTXF) has announced groundbreaking research published in Cells regarding how its ACP-01 and NCP-01 cell therapies could potentially improve brain-computer interface (BCI) longevity and performance.
The research demonstrates how these autologous blood-derived cell precursors could address key limitations of BCIs, which currently fail within 6 months to 1 year. ACP-01 produces signals that suppress inflammation and support blood vessel growth, while NCP-01 promotes neural plasticity and new synaptic connections.
The company sees potential for licensing opportunities with BCI technology companies to combine their stem-cell therapy with cutting-edge neural interfaces, aiming to extend implant longevity from months to potentially a lifetime while improving signal fidelity and learning capabilities.
Hemostemix (OTCQB: HMTXF) has successfully completed a non-brokered private placement, raising $2,969,600 through the sale of 29,696,000 units at $0.10 per unit. Each unit comprises one common share and one warrant exercisable at $0.15 for two years.
The company will use the proceeds to repay CD#1 at a 50% discount to face value ($1,250,000) and for general working capital, including marketing and sales of VesCell™. The placement included participation from directors Peter Lacey and Loran Swanberg. Additionally, Hemostemix granted 3,870,000 stock options to directors, officers, employees, and consultants at $0.13 per share, expiring July 23, 2030.
Hemostemix (OTCQB: HMTXF) has announced the closing of a sale of 15 ACP-01 Therapy Convertible Debentures (TCD) for USD $517,230, pending TSXV Exchange approval. The TCDs are convertible into ACP-01 therapy treatments or common shares at $0.155 per share, featuring a 6% annual interest rate payable in shares and a maturity date of December 31, 2029.
As an autologous stem cell therapy company, Hemostemix has successfully treated 498 patients for various cardiovascular diseases. The company's ACP-01 therapy has demonstrated clinical significance in treating conditions including peripheral arterial disease, chronic limb threatening ischemia, and various forms of heart disease. The new TCD structure enables the company to sell therapy blocks to clinics, investors, and high-net-worth individuals without diluting shareholder equity.
[ "Introduction of innovative TCD financing structure that allows forward sale of treatments without equity dilution", "Successfully treated 498 patients and completed 7 clinical studies with 318 subjects", "Demonstrated clinical significance in multiple cardiovascular conditions", "6% annual interest rate on TCDs provides additional value to investors" ]Hemostemix (OTCQB: HMTXF) has expanded its previously announced private placement from $2.5 million to $3 million due to oversubscription. The company is offering Units at $0.10 each, consisting of one Common Share and one Warrant exercisable at $0.15 for two years.
Notable insider participation includes Chairman Peter Lacey ($1.5 million) and Director Loran Swanberg ($100,000). The proceeds will be used to repay CD#1 at a 50% discount to face value ($1.25 million) and for general working capital to support operational expenses, including marketing and sales of VesCell™.
Hemostemix (OTCQB: HMTXF) has announced an oversubscribed private placement, raising $2.7 million through a non-brokered offering, exceeding the initial target of $2.5 million. The company is issuing units at $0.10, with each unit comprising one common share and one warrant exercisable at $0.15 for two years.
Chairman Peter Lacey led the placement with a $1.5 million subscription. Additionally, the company has negotiated a debt settlement of $400,000 at $0.20 per share. Proceeds will be used to repay CD#1 and support working capital, including marketing and sales of VesCell™.
Hemostemix (OTCQB: HMTXF) has successfully closed a non-brokered private placement offering, raising CAD $469,366 through the issuance of 3,911,385 Common Shares at CAD $0.12 per share. The TSX Venture Exchange has granted conditional approval for this offering.
The funds will be directed towards general working capital, operational expenses, and business development activities. The issued securities are subject to a four-month hold period under Canadian securities laws. The investor is confirmed to be arm's length to the company and not a Related Party.
Hemostemix (OTCQB: HMTXF) has published its 10th scientific paper detailing ACP-01's molecular strategy for treating heart failure, specifically focusing on non-ischemic dilated cardiomyopathy (DCM). The publication highlights how ACP-01's unique characteristics differentiate it from traditional bone marrow-derived cell therapies.
The company's previous studies demonstrated that cardiac function improved by up to 47.1% after one ACP-01 treatment in DCM patients. ACP-01's effectiveness is attributed to three key mechanisms: precise migration to injured tissue through CXCR4 expression, attraction of Natural Killer cells to reduce inflammation and fibrosis, and improved microcirculation through angiogenesis.
Following Florida's new law permitting non-FDA approved stem cell treatments, Hemostemix is now offering ACP-01 therapy to no-option DCM patients in Florida.
FAQ
What is the current stock price of Hemostemix (HMTXF)?
What is the market cap of Hemostemix (HMTXF)?
